The Role of Cytokines in Acute and Chronic Inflammation

Cytokines are small signaling proteins that immune cells release to coordinate the body’s inflammatory response, and they serve as both the alarm system that launches acute inflammation and the persistent background noise that sustains chronic inflammation when something goes wrong. Pro-inflammatory cytokines recruit immune cells and ramp up tissue defenses, while anti-inflammatory cytokines dial things back and promote healing. The balance between those two sides determines whether inflammation resolves cleanly or spirals into lasting damage, and disrupting that balance sits at the heart of conditions from rheumatoid arthritis to sepsis.

How Cytokines Kick Off Acute Inflammation

When tissue is injured or infected, immune cells at the site release a burst of pro-inflammatory cytokines. The headliners in the early response are tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). These molecules do not attack pathogens directly. Instead, they change the behavior of surrounding cells, particularly the endothelial cells lining blood vessels. TNF-α, for instance, increases the permeability of pulmonary blood vessel walls, causing fluid and proteins to leak into surrounding tissue. In animal studies, recombinant TNF-α increased lung fluid accumulation and caused visible endothelial injury under electron microscopy.¹ Both TNF and IL-1α directly increase vascular permeability in a time- and dose-dependent fashion, an effect that researchers have linked to the kind of vascular injury seen in septic shock.²

That leakiness is not a defect. It is the point. Making blood vessels more permeable allows white blood cells and defensive proteins to flood into the damaged area. IL-1β plays a central role in pulling neutrophils, the first-responder white blood cells, out of the bloodstream and into tissue. In a mouse model of skin infection, early upregulation of IL-1β through an intracellular alarm complex called the inflammasome drove prominent neutrophil recruitment to the infection site.³ A similar mechanism has been observed during influenza infection, where mice that produced more IL-1β in the lungs recruited more neutrophils and were better protected against the virus.⁴ Pro-inflammatory interleukins activate and recruit immune cells, while anti-inflammatory interleukins work to suppress excessive inflammation and promote tissue repair once the threat is handled.⁵

Why a Local Wound Can Make Your Whole Body React

Acute inflammation does not always stay local. When cytokine levels climb high enough, they enter the bloodstream and trigger body-wide effects: fever, fatigue, changes in appetite, and a shift in what the liver produces. IL-6 is the main driver of that systemic shift. It acts on liver cells to ramp up production of so-called acute phase proteins, including C-reactive protein (CRP), serum amyloid A, and fibrinogen, while simultaneously reducing production of albumin and transferrin. IL-6 is the only cytokine that stimulates the full range of acute phase proteins seen during human inflammation.⁶

IL-6 does not work entirely alone. IL-1-type cytokines also act on liver cells, and the two families can have additive or synergistic effects on acute phase protein output.⁷ This is why a blood test showing elevated CRP can indicate inflammation somewhere in the body without telling you where. The liver is responding to cytokine signals that may originate from a joint, the lungs, or an infected wound. More than 50 cytokines relay their signals into cells through a shared internal pathway called JAK/STAT, which controls blood cell production, inflammation, and immune responses.⁸ That shared wiring explains why so many different cytokines can produce overlapping symptoms and why blocking just one pathway sometimes has surprisingly broad effects.

How Inflammation Is Supposed to End

A healthy inflammatory episode has a built-in off switch. Once the threat is neutralized, the cytokine balance shifts from pro-inflammatory signals toward anti-inflammatory ones. The two most important shutdown molecules are IL-10 and transforming growth factor beta (TGF-β). IL-10 dampens pro-inflammatory signals by inhibiting the release of cytokines like TNF-α and interferon-gamma. TGF-β helps restore immune order partly by encouraging the development of regulatory T cells that suppress ongoing immune activity.⁹

Gout offers a vivid natural example. During an acute gout flare, crystals in the joint trigger a wave of pro-inflammatory cytokines. Yet the attack typically resolves on its own within days. Studies of fluid from gouty joints show that this spontaneous resolution is accompanied by a rapid rise in TGF-β1, IL-10, IL-1 receptor antagonist, and soluble TNF receptors, all of which counteract the molecules that started the inflammation.¹⁰ Inflammation, in other words, is designed to be self-limiting. The problems start when that off switch fails.

What Happens When Inflammation Becomes Chronic

Chronic inflammation is, at its simplest, a failure of resolution. The pro-inflammatory cytokines IL-1 and TNF-α are targets of signaling pathways that can create feed-forward loops, where the production of these cytokines activates pathways that produce even more of them.¹¹ If the anti-inflammatory arm does not match that escalation, inflammation becomes self-sustaining even after the original trigger is gone.

Macrophages, large immune cells that patrol tissues and engulf debris, are central players in this dynamic. They can shift between two broad functional states. M1-type macrophages promote inflammation, producing TNF-α and other pro-inflammatory cytokines. M2-type macrophages suppress inflammation and encourage tissue repair. Maintaining a stable ratio between the two is critical for returning to normal after an immune challenge.¹² The switch between M1 and M2 is not permanent. It is plastic, meaning the surrounding cytokine environment can push macrophages from one state to the other. Experiments with fungal infection showed that macrophages fully polarized toward a pro-inflammatory M1 state could be reprogrammed toward an anti-inflammatory M2 state simply by changing the cytokines they were exposed to, and vice versa.¹³ In chronic disease, the cytokine environment often favors a persistent M1 state, keeping inflammation locked on.

Cytokines in Autoimmune Disease

Autoimmune diseases are among the clearest examples of chronic cytokine-driven inflammation. In rheumatoid arthritis, psoriasis, and other autoimmune conditions, the immune system attacks the body’s own tissues, and specific cytokines sustain that attack. IL-17, produced primarily by a subset of helper T cells, strongly contributes to the chronic inflammation underlying diseases like rheumatoid arthritis.¹⁴ Both helper T cells producing IL-17 (Th17 cells) and killer T cells producing similar cytokines have been implicated in sustaining chronic autoimmune inflammation in experimental models.¹⁵

The fact that different autoimmune diseases are driven by different cytokine signatures is what makes targeted therapy possible. Rheumatoid arthritis involves TNF-α, IL-6, and IL-17 prominently, while conditions like lupus feature a stronger interferon signature. This is not academic trivia. It explains why a drug that works beautifully for one autoimmune disease might do nothing for another, even though both involve “chronic inflammation.” The cytokine profile is different, so the therapeutic target has to be different.

When the Immune System Overshoots Catastrophically

At the extreme end of acute cytokine activity sits the cytokine storm, a massive, uncontrolled release of pro-inflammatory cytokines that damages the body’s own organs. Cytokine storms are the primary driver of multi-organ failure in severe infections, certain cancer immunotherapies, and some genetic conditions. They are triggered when the normal amplification loops of inflammation spin out of control and negative feedback mechanisms fail.¹⁶ The immune system succeeds in attacking the pathogen but inflicts catastrophic collateral damage in the process. COVID-19 brought this concept into public awareness, but cytokine storms were well described in sepsis and in reactions to CAR-T cell therapy long before the pandemic.

Detecting an emerging cytokine storm early enough to intervene is a major clinical goal. In blunt trauma patients, a panel of eight cytokine biomarkers, including IL-6, IL-10, and several growth factors, could discriminate between patients who would develop sepsis and those who would not, with high accuracy. Levels of those cytokines showed abrupt changes up to 72 hours before clinically obvious deterioration.¹⁷ Newer point-of-care platforms using artificial intelligence and multiplexed sensors can now measure multiple cytokines simultaneously from tiny blood samples, delivering results in minutes rather than hours.¹⁸ The hope is that bedside cytokine monitoring will eventually let clinicians intervene before full-blown organ failure sets in.

Fibrosis and Tissue Scarring

Chronic inflammation does not just cause pain and swelling. Over time, it remodels tissue. TGF-β, the same cytokine that helps resolve acute inflammation, becomes a villain in a chronic setting. When TGF-β signaling is persistently elevated, it drives fibrosis, the replacement of normal tissue with scar-like connective tissue that does not function properly.¹⁹ Defects in TGF-β signaling in epithelial cells, fibroblasts, and immune cells disrupt immune tolerance, promote inflammation, and underlie the pathology of both fibrosis and cancer.²⁰

This dual role of TGF-β is one of the trickiest problems in cytokine biology. Blocking it might reduce fibrosis, but could also unleash uncontrolled inflammation or impair wound healing. The context matters enormously: the same molecule can be protective or destructive depending on which tissue it acts in, how long the signal lasts, and what other cytokines are present at the same time.

Drugs That Target Cytokines Directly

The recognition that specific cytokines drive specific diseases opened the door to a class of drugs called biologics, engineered antibodies or receptor blockers that neutralize individual cytokines. TNF inhibitors were the first big success story, transforming the treatment of rheumatoid arthritis, Crohn’s disease, and psoriasis starting in the late 1990s. IL-6 receptor inhibitors followed. In a trial of rheumatoid arthritis patients who had already failed TNF-blocking drugs, the IL-6 receptor blocker tocilizumab combined with methotrexate produced rapid and sustained improvements.²¹ Registry data comparing TNF inhibitors with IL-6 receptor inhibitors in real-world patients have generally found comparable effectiveness for disease activity and patient-reported outcomes.²²

A newer approach targets the signaling machinery inside cells rather than the cytokines themselves. JAK inhibitors are small molecules that block the JAK/STAT pathway through which many cytokines relay their signals. Because dozens of cytokines use this pathway, JAK inhibitors suppress signaling from multiple inflammatory mediators at once, which gives them broad anti-inflammatory effects across rheumatoid arthritis and other immune-mediated diseases.²³ That breadth is both their strength and a source of concern about side effects.

The Infection Trade-Off With Cytokine-Blocking Therapy

Suppressing cytokines to treat autoimmune disease comes with a clear trade-off: those same cytokines are needed to fight infections. TNF-α, for example, is critical for containing tuberculosis. A systematic review of randomized controlled trials found that TB reactivation occurred in about 0.26% of patients on anti-TNF therapy, compared to zero cases in control groups. The risk climbed further when anti-TNF drugs were combined with other immunosuppressants like methotrexate.²⁴ JAK inhibitors carry a similar burden. In pooled data from clinical trials of the JAK inhibitor tofacitinib, the rate of tuberculosis was about 0.21 per 100 patient-years, and overall opportunistic infections occurred at roughly 0.46 per 100 patient-years.²⁵ This is why patients starting biologic or JAK inhibitor therapy are screened for latent tuberculosis and monitored for unusual infections throughout treatment.

Aging and the Slow Burn of “Inflammaging”

You do not need a disease to develop chronic low-grade inflammation. Aging itself does it. As cells age, they enter a state called senescence, where they stop dividing but do not die. Instead, senescent cells release a cocktail of cytokines, including IL-1, IL-6, IL-8, TNF-α, and TGF-β, that promotes a mild but persistent inflammatory environment. This phenomenon, sometimes called “inflammaging,” creates the backdrop for age-related cardiovascular diseases like atherosclerosis and coronary heart disease.²⁶

Environmental exposure adds to the burden. Particulate matter air pollution, for example, drives a general upward trend in pro-inflammatory cytokines across multiple organs in animal studies, including the lungs, heart, liver, and brain. Anti-inflammatory IL-10 initially rises to compensate but can fall off in some organs over extended exposure, suggesting the resolution machinery eventually becomes overwhelmed.²⁷ Aging, pollution, poor sleep, and metabolic stress all feed into the same low-grade cytokine elevation, which helps explain why so many chronic diseases cluster together in older adults.

Cytokines, Fat Tissue, and Metabolic Inflammation

Adipose tissue is not an inert energy warehouse. It is an active immune organ that produces cytokines and chemokines, especially when it expands during weight gain. Visceral fat, the deep belly fat surrounding organs, is particularly active. Dysfunctional fat cells secrete inflammatory adipokines and attract bone marrow-derived immune cells that amplify the inflammatory signal.²⁸ This adipose-driven inflammation contributes directly to insulin resistance, type 2 diabetes, and cardiovascular disease. It also means that weight loss can reduce systemic inflammation not just by lightening mechanical load on joints but by actually shrinking a source of pro-inflammatory cytokine production.

The Gut Microbiome as a Cytokine Regulator

The trillions of bacteria living in the gut influence cytokine levels throughout the body. Microbial metabolites, including short-chain fatty acids from dietary fiber, tryptophan breakdown products, and modified bile acids, directly and indirectly modulate immune cell activation and cytokine secretion.²⁹ Short-chain fatty acids, for instance, tend to promote anti-inflammatory responses and strengthen the gut lining. When microbial diversity drops, as it does with poor diet, antibiotic use, or chronic stress, the balance can shift toward a more pro-inflammatory cytokine profile at the gut lining and beyond. This crosstalk between gut bacteria and cytokines is one of the reasons dietary patterns show up in studies of inflammatory diseases: the food you eat reshapes the microbial community, which in turn reshapes the cytokine environment.

Cytokines and the Brain

The brain was once considered an immune-privileged zone, sealed off from the body’s inflammatory machinery by the blood-brain barrier. That picture has gotten more complicated. Microglia, the brain’s resident immune cells, produce cytokines when activated, and those cytokines can weaken the blood-brain barrier itself. Activated microglia release TNF-α, IL-1β, IL-6, and a range of chemokines, which reduce the expression of tight junction proteins that normally keep the barrier sealed. In laboratory models, activated microglia significantly decreased barrier integrity, collapsed tight junction structures, and increased the passage of molecules that normally cannot cross.³⁰ This two-way relationship, where microglia weaken the barrier and the barrier state influences microglial activation, creates the potential for self-reinforcing neuroinflammatory cycles.³¹

Neuroinflammation driven by cytokines is now thought to play a role in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and depression. Peripheral inflammation, the kind generated by obesity or a chronic infection elsewhere in the body, can reach the brain through a compromised barrier or by direct signaling at barrier-adjacent structures. This is one plausible mechanism behind the observation that people with chronic inflammatory conditions have higher rates of depression and cognitive decline.

An Ancient System, Not a Modern Invention

The cytokine machinery driving inflammation is not a recent evolutionary innovation confined to mammals. Researchers using protein structure prediction have identified a family of IL-1-related proteins with counterparts across all animals with true tissues, from sea urchins and lampreys to humans. These ancestral IL-1 proteins share expression patterns, cellular localization, and processing features with mammalian IL-1α and IL-1β, suggesting that IL-1 signaling and its associated circuitry represent a foundational module of animal immunity that far predates the evolution of jaws, let alone adaptive immunity.³² The deep conservation of these molecules underscores how fundamental cytokine-driven inflammation is to survival. The system has been refined and expanded over hundreds of millions of years, but its core logic, rapid signaling to mount a defense and then shut it down, has been running since before vertebrates existed.